

**Translation**

Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

**Summary of Consolidated Financial Results  
for the Nine Months Ended December 31, 2022  
(Based on Japanese GAAP)**

February 9, 2023

Company name: Japan Animal Referral Medical Center (JARMec)  
 Stock exchange listing: Tokyo  
 Stock code: 6039 URL <http://www.jarmec.co.jp>  
 Representative: Representative Director and President Hidehiro Hirao  
 Executive Director, Finance and Administration Takayuki Ishikawa TEL 044(850)1320  
 Inquiries: Administration  
 Scheduled date to file Quarterly Securities Report: February 13, 2023  
 Scheduled date to commence dividend payments: –  
 Preparation of supplementary material on quarterly financial results: Yes  
 Holding of quarterly financial results meeting: No

(Amounts less than one million yen are rounded down)

1. Consolidated financial results for the nine months ended December 31, 2022 (from April 1, 2022 to December 31, 2022)

(1) Consolidated operating results (cumulative)

Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Nine months ended December 31, 2022	2,915	30.7	456	38.1	421	27.4	279	25.0
Nine months ended December 31, 2021	2,230	4.6	330	11.8	330	11.4	223	9.6

	Earnings per share	Diluted earnings per share
	Yen	Yen
Nine months ended December 31, 2022	119.75	117.20
Nine months ended December 31, 2021	93.96	91.64

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
	Millions of yen	Millions of yen	%
As of December 31, 2022	8,097	3,603	44.5
As of March 31, 2022	7,107	2,509	35.3

2. Cash dividends

	Annual dividends per share				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2022	–	0.00	–	0.00	0.00
Year ending March 31, 2023	–	0.00	–		
Year ending March 31, 2023 (Forecast)				0.00	0.00

3. Forecast of consolidated financial results for the year ending March 31, 2023 (from April 1, 2022 to March 31, 2023)

Percentages indicate year-on-year changes

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	3,860	29.6	535	21.8	540	22.9	365	27.2	149.94

4. Notes

- (1) Changes in significant subsidiaries during the nine months ended December 31, 2022  
(changes in specified subsidiaries resulting in the change in scope of consolidation): No
- (2) Application of special accounting methods for preparing quarterly consolidated financial statements: Yes
- (3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements
- Changes in accounting policies due to revisions to accounting standards and other regulations: No
- Changes in accounting policies due to other reasons: No
- Changes in accounting estimates: No
- Restatement of prior period financial statements: No

(4) Number of issued shares (common shares)

Total number of issued shares at the end of the period (including treasury shares)

As of December 31, 2022	2,836,200 shares	As of March 31, 2022	2,436,200 shares
-------------------------	------------------	----------------------	------------------

Number of treasury shares at the end of the period

As of December 31, 2022	104,616 shares	As of March 31, 2022	109,616 shares
-------------------------	----------------	----------------------	----------------

Average number of shares during the period (cumulative from the beginning of the fiscal year)

Nine months ended December 31, 2022	2,336,967 shares	Nine months ended December 31, 2021	2,382,922 shares
-------------------------------------	------------------	-------------------------------------	------------------

**Quarterly consolidated financial statements**  
**Consolidated balance sheets**

(Thousands of yen)

	As of March 31, 2022	As of December 31, 2022
<b>Assets</b>		
Current assets		
Cash and deposits	1,068,595	1,946,206
Accounts receivable - trade, and contract assets	228,993	248,556
Merchandise	119,070	121,534
Raw materials and supplies	9,760	9,673
Other	121,148	46,923
Allowance for doubtful accounts	(7,790)	(7,065)
Total current assets	1,539,777	2,365,828
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	1,531,803	1,457,490
Land	2,248,337	2,248,337
Other, net	929,346	1,193,973
Total property, plant and equipment	4,709,488	4,899,802
Intangible assets		
Goodwill	203,698	188,421
Trademark right	435,464	402,804
Other	26,279	21,290
Total intangible assets	665,442	612,516
Investments and other assets	192,889	219,182
Total non-current assets	5,567,820	5,731,500
Total assets	7,107,598	8,097,328
<b>Liabilities</b>		
Current liabilities		
Accounts payable - trade	65,642	66,182
Current portion of long-term borrowings	546,376	560,886
Income taxes payable	88,562	97,232
Provision for bonuses	79,335	44,615
Other	185,796	246,729
Total current liabilities	965,713	1,015,646
Non-current liabilities		
Long-term borrowings	3,375,581	3,250,067
Retirement benefit liability	27,100	31,600
Deferred tax liabilities	165,696	137,181
Asset retirement obligations	40,501	40,982
Other	23,081	18,375
Total non-current liabilities	3,631,961	3,478,205
Total liabilities	4,597,674	4,493,852
<b>Net assets</b>		
Shareholders' equity		
Share capital	385,500	791,100
Capital surplus	315,717	715,328
Retained earnings	1,994,792	2,274,645
Treasury shares	(186,086)	(177,598)
Total shareholders' equity	2,509,923	3,603,476
Total net assets	2,509,923	3,603,476
Total liabilities and net assets	7,107,598	8,097,328

**Consolidated statements of income (cumulative) and consolidated statements of comprehensive income (cumulative)**

**Consolidated statements of income (cumulative)**

	(Thousands of yen)	
	Nine months ended December 31, 2021	Nine months ended December 31, 2022
Net sales	2,230,636	2,915,250
Cost of sales	1,403,608	1,817,754
Gross profit	827,027	1,097,495
Selling, general and administrative expenses	496,127	640,631
Operating profit	330,900	456,863
Non-operating income		
Rental income from buildings	17,520	17,520
Gain on sale of goods	–	5,518
Other	3,148	8,484
Total non-operating income	20,669	31,524
Non-operating expenses		
Interest expenses	9,197	13,362
Financing expenses	10,266	3,374
Loss on retirement of non-current assets	1,013	11,607
Share issuance costs	–	35,948
Other	246	2,616
Total non-operating expenses	20,723	66,909
Ordinary profit	330,845	421,478
Extraordinary income		
Gain on sale of non-current assets	–	28
Total extraordinary income	–	28
Extraordinary losses		
Office Transfer related Expenses	6,282	–
Total extraordinary losses	6,282	–
Profit before income taxes	324,563	421,506
Income taxes	100,658	141,653
Profit	223,905	279,853
Profit attributable to owners of parent	223,905	279,853

**Consolidated statements of comprehensive income (cumulative)**

(Thousands of yen)

	Nine months ended December 31, 2021	Nine months ended December 31, 2022
Profit	223,905	279,853
Comprehensive income	223,905	279,853
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	223,905	279,853